Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

By L. Kappos, David K. B. Li, Peter A. Calabresi, P. O'Connor, A. Bar-Or, Frederik Barkhof, M. Yin, D. Leppert, R. Glanzman, J. Tinbergen and 1 more. The Lancet, 2011

700 citations recorded by the source corpus.